BCL2 and neoplasm: Previous research reported that elevated p53 expression and a higher Bax/Bcl-2 ratio correlate with increased tumor sensitivity to anticancer therapies [23], further supporting the potential of the A. incana DCM fraction as a therapeutic agent.